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Abstract Enzyme replacement therapy (ERT) is an effective
treatment for several lysosomal storage disorders (LSDs). In-
travenously infused enzymes are taken up by tissues through
either the mannose 6-phosphate receptor (M6PR) or the man-
nose receptor (MR). It is generally believed that M6PR-
mediated endocytosis is a key mechanism for ERT in treating
LSDs that affect the non-macrophage cells of visceral organs.
However, the therapeutic efficacy ofMR-mediated delivery of
mannose-terminated enzymes in these diseases has not been
fully evaluated. We tested the effectiveness of a non-
phosphorylated α-galactosidase A produced from moss
(referred to as moss-aGal) in vitro and in a mouse model of
Fabry disease. Endocytosis of moss-aGal was MR-dependent.
Compared to agalsidase alfa, a phosphorylated form of α-
galactosidase A, moss-aGal was more preferentially targeted
to the kidney. Cellular localization of moss-aGal and
agalsidase alfa in the heart and kidney was essentially identi-
cal. A single injection of moss-aGal led to clearance of
accumulated substrate in the heart and kidney to an extent
comparable to that achieved by agalsidase alfa. This study
suggested that mannose-terminated enzymes may be suffi-
ciently effective for some LSDs in which non-macrophage
cells are affected, and that M6P residues may not always be
a prerequisite for ERT as previously considered.
Introduction
Lysosomal storage diseases (LSDs) are a group of life-
threatening inherited disorders; most are caused by deficiency
of a single lysosomal enzyme or protein, which leads to accu-
mulation of substrate in cells. Currently, enzyme replacement
therapy (ERT) is the principal specific treatment for several
LSDs. Traditionally, the recombinant enzymes used in ERT
are produced in cultured mammalian cells. Recently, as an
alternative approach, plant-based expression systems have
been utilized to produce lysosomal enzymes for therapeutic
use (Shaaltiel et al 2007; Du et al 2008; He et al 2012). Rel-
ative to mammalian cell-based systems, plant-based systems
have several advantages including lower production costs,
eliminated risk of contamination by mammalian pathogens
and, in the case of moss, a relatively easier manipulation of
the N-glycosylation pathway. However, a major concern when
considering using plant cell-produced enzymes for ERT is
their N-glycan structures that usually differ from mammalian
cell-produced enzymes. Particularly, lysosomal enzymes
expressed in plant cells typically do not acquire mannose 6-
phosphate (M6P) modification on terminal mannose residues
(Gomord and Faye 2004).
Intravenously administered lysosomal enzymes are taken
up by tissues through cell surface receptors that recognize the
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carbohydrate structure of the enzymes. M6P receptor
(M6PR) and mannose receptor (MR) represent two major
contributors to this uptake system. M6PR recognizes phos-
phorylated terminal mannose residues (M6P) and is
expressed in most cell types (Kornfeld 1992). It is gener-
ally believed that in ERT used for most LSDs the M6PR-
mediated endocytic pathway is crucial for sufficient en-
zyme delivery (Sands et al 2001; Sly et al 2006). On
the other hand, MR recognizes terminal mannose, fucose
and N-acetylglucosamine (GlcNAc) residues of glycopro-
teins (Stahl and Ezekowitz 1998). It was initially thought
that the expression of MR is restricted to tissue macro-
phages, but now it is known that MR is also expressed in
many other cell types including dendritic, endothelial,
smooth muscle, and kidney mesangial cells (Stahl and
Ezekowitz 1998). Mannose-terminated enzymes are
thought to be effective in LSDs that affect macrophages,
such as Gaucher disease (Barton et al 1991). Previous
studies also demonstrated macrophage-targeted delivery of
mannose-terminated protective protein/cathepsin A
(PPCA), neuraminidase, and lysosomal acid lipase in ani-
mal models (Bonten et al 2004; Du et al 2008). However,
the therapeutic efficacy of MR-mediated enzyme delivery
in LSDs in which parenchymal (non-macrophage) cells are
affected has not been fully evaluated.
In this study we addressed this question in Fabry
disease, a glycosphingolipidosis caused by deficient ac-
tivity of α-galactosidase A (α-gal A)(Brady et al 1967).
As a result of the enzymatic defect, glycosphingolipids
with terminal α-D-galactosyl residues, predominantly
globotriaosylceramide (Gb3), accumulate in virtually all
organs. Fabry disease exhibits a variety of clinical man-
ifestations, of which stroke, cardiac dysfunction, and
renal impairment are the most life threatening (Desnick
et al 2001). Currently, two recombinant α-gal A prepa-
rations, agalsidase beta and agalsidase alfa, are used for
ERT for Fabry disease (Eng et al 2001a, b; Schiffmann
et al 2001). Both are produced from mammalian cells
and contain M6P (Lee et al 2003). ERT with these
enzymes is effective in reducing glycolipids accumula-
tion in tissues, and appears to slow progression of the
disease (Pastores 2007). In general, however, ERT does
not produce completely satisfactory results when initiat-
ed in adults. Further investigations, including develop-
ment of new forms of the enzyme and a better under-
standing of the mechanism of enzymatic uptake, are
needed to improve the therapeutic outcome of ERT for
this disease. In this study, we tested the enzymology,
pharmacokinetics and pharmacodynamics of a new form
of α-gal A in patient-derived cell lines and a mouse
model of Fabry disease. This enzyme was produced




The DNA encoding human α-gal A (NCBI Reference:
NM_000169.2) was synthesized as a codon-optimized (for
Physcomitrella patens) version and sub-cloned into a moss
expression vector.
To generate α-gal A-producing moss cell lines, protoplasts
of a moss double-knockout line devoid of plant specificα-1,3-
fucose andβ-1,2-xylose residues on its N-glycans (Koprivova
et al 2004) were transformed with the expression cassettes by
a PEG-based method and were selected using G418. More
than 2000 drug-resistant moss plantlets were screened for total
moss-aGal accumulation per biomass, and the strain with the
highest expression was chosen as the production strain (for
moss-aGal).
To produce α-gal A with increased numbers of terminal
mannose (high-mann moss-aGal), the above production strain
was further transformed with a knockout construct targeting
N-acetylglucosaminyltransferase I gene.
Enzyme production and purification
Themoss-aGal production strain was cultivated for 4 weeks in
a 20 L disposable bag placed in a Wave™ Reactor Rocker. At
the end of cultivation, the culture broth was clarified and con-
centrated. Mossα-gal A enzymes were purified by three chro-
matographic steps (Butyl-650M, DEAE, S) and were concen-




α-Gal A activity was measured by the fluorimetric method as





In vitro uptake study
Fabry patient-derived skin fibroblasts (DMN96.125) and en-
dothelial cell line (IMFE1)(Shen et al 2007) were cultured in
10 % FBS in DMEM and EGM-2MV (Lonza) respectively.
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The cells were incubatedwithα-gal A preparations (10μg/ml)
in the presence or absence of inhibitors for indicated time
lengths. After that, cells were harvested (by trypsin treatment
that also eliminates extracellular α-gal A) for enzyme assay or
immunoblot. For binding studies, IMFE1 cells were incubated
with enzymes for 3 h at 4 °C. Then, the cells were washedwith
ice-cold PBS and directly lysed in 0.2 % Triton for α-gal A
assay.
In uptake/binding studies, we used enzyme concentration
of 10 μg/ml, which is in the range of theoretical maximum
plasma concentrations of agalsidase alfa and beta (~5 and
20 μg/ml respectively) in infused patients receiving approved
doses. A pilot study showed that uptake of both moss-aGal
and agalsidase alfa in IMFE1 cells was dose-dependent up to
40 μg/ml (Supplementary Fig. 1), indicating that 10 μg/ml is
below the saturation concentration.
SDS-PAGE and western blot
See Supplementary materials.
Immunofluorescence of cultured cells
See Supplementary materials.
Animals and procedures
Both knockout Fabry mice (Ohshima et al 1997) and WT
controls used in this study have mixed genetic background
of C57BL/6J and 129 strains with ~75 % of C57BL/6J strain
background (Shen et al 2015). Fabry mice accumulate Gb3 in
most organs, thus mimicking Fabry disease biochemically.
Preclinical ERT studies in Fabry mice permitted evaluation
of the pharmacokinetics, biodistribution and dose-dependent
substrate clearance of infused α-gal A (Ioannou et al 2001).
Besides proof-of-concept, these data provided important in-
formation for determining the dosing regimen in clinical trials.
Although there is only limited information for biodistribution
of the enzyme in patients, it appears that plasma clearance,
cellular localization, and tissue half-life of infused α-gal A
in humans (Schiffmann et al 2000; Eng et al 2001a, b) are
similar to those in Fabry mice (Ioannou et al 2001; Murray
et al 2007). In addition to a number of ERT studies, Fabry
mice have also been proven to be an invaluable preclinical
model to test biochemical and functional correction of Fabry
disease by gene therapy and substrate reduction therapy
(Ziegler et al 2007; Ashe et al 2015).
All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committee of Baylor Re-
search Institute. Female Fabry mice (3–6 months old) were
used throughout the study. For Gb3 clearance studies, female
Fabry mice are better suited than male Fabry mice (Durant
et al 2011), because male mice have testosterone-induced
Gb3 synthesis in kidneys that confounds the effect of the in-
fused enzyme in degrading accumulated Gb3. For all the in-
jections, enzymes were diluted in saline to a total volume of
200 μl per mouse and were injected via tail-vein. Because of
the limited availability of agalsidase beta, only agalsidase alfa
was used in animal studies for comparison with moss-aGal.
Pharmacokinetics
Enzyme preparations were injected at a dose of 1 mg/kg body
weight (BW) (n=5). Blood samples were collected by tail
bleed at indicated time points. Plasma was separated for en-
zyme assay.
Biodistribution and tissue kinetics
Enzymes were injected at 1 mg/kg BW. At indicated time
points, mice were perfused with saline (to remove blood),
and heart, kidneys, spleen, and liver were harvested. The
whole organs were homogenized in 0.2 % Triton/saline for
enzyme assay.
Immunohistochemistry
Heart and kidney were harvested 1 day after enzyme infusion
(1 mg/kg). Immunohistochemistry for human α-gal A was
performed using a rabbit polyclonal antibody (see
Supplementary materials).
Clearance of tissue Gb3
Six-month-old female Fabry mice were injected with enzymes
at doses of 0.3, 1, and 3 mg/kg BW. Heart, kidney, and liver
were harvested 1 week after a single injection. Tissue Gb3
levels were analyzed by mass-spectrometry as described (Du-
rant et al 2011).
Statistical analysis
Data were presented as mean±SEM. Statistical significance
was determined by the Student’s t-test.
Results
Production and purification of moss enzymes
Human α-gal A was stably overexpressed in the moss
Physcomitrella patens. The α-gal A expressing moss strain
was a glycoengineered variant devoid of α-1,3-fucose and
β-1,2-xylose residues on its N-glycans that are plant-specific
and may elicit immunogenic response in mammals
(Koprivova et al 2004). In the expression construct, N-
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terminal signal sequence of humanGLA gene was replaced by
a plant secretory signal peptide which is removed by signal-
peptidase upon translation. The construct does not contain C-
terminal vacuolar targeting sequence, which is often added to
the protein of interest in plant expression systems to achieve
mannose-terminated N-glycans. Therefore, the protein se-
quence of secreted moss-aGal is identical to the native human
α-gal A (with signal peptide removed).
Production of moss-aGal was accomplished in a photoau-
totrophic fermentation process. The moss was grown in a pure
mineral culture medium without any antibiotics or animal-
derived component. Because of the lack of C-terminal vacu-
olar signal, moss-aGal is secreted into the culture medium
instead of being sorted to the vacuoles. Recombinant α-gal
A secreted in the mediumwas purified by column chromatog-
raphy with a typical recovery rate of 30 %. The purified moss-
aGal had 99 % purity by size exclusion chromatography and
contained low levels (~100 ppm) of host cell proteins.
To test the effect of the increased number of terminal
mannosyl residues on cellular uptake of the enzyme, α-gal
Awas also produced in a strain that was genetically depleted
of its β-1,2-N-acetylglucosaminyltransferase activity. This
knockout-modification results in an incapability of the moss
to perform any complex-type glycan processing, as all later
enzymatic steps lack their substrate. Hence, α-mannosidase I-
mediated trimming in the cis-Golgi is the last processing step
and therefore all N-glycans of this strain are of the high-
mannose type. Human α-gal A produced in this strain is re-
ferred to as high-mann moss-aGal.
In vitro characterization
Moss-aGal had very uniform N-glycans with core-type
Man3GlcNAc2 as dominant structure (Table 1). Carbohydrate
chains of moss-aGal were almost exclusively constituted of
mannose and GlcNAc; both are MR ligands. In comparison,
Man5GlcNAc2 was the most abundant glycan structure in
high-mann moss-aGal (Table 1) with some small amounts of
Man4, Man6, and Man7. There were no phosphorylated gly-
cans in either moss-aGal or high-mann moss-aGal. Agalsidase
alfa showed highly heterogeneous glycan structures, of which
~24 % were phosphorylated, ~7 % were mannose-terminated,
and 63 % were diverse structures.
In SDS-PAGE, moss-aGal was detected as a single major
band with a faster mobility than agalsidase alfa (Fig. 1a),
reflecting the lower carbohydrate content in moss-aGal. After
removal of N-glycans by PNGase F, both moss-aGal and
agalsidase alfa migrated to the same position (Fig. 1a). In
western blot, both moss-aGal and agalsidase alfa were detect-
ed by a polyclonal antibody to human α-gal A (Fig. 1b). With
the same amount of protein loaded, the intensity of moss-aGal
band in immunoblot was 2.14±0.58 times (n=3) that of
agalsidase alfa.
Specific activities of moss-aGal and high-mann moss-aGal
were similar to those of agalsidase alfa and beta (Fig. 1c).
Enzyme kinetics of moss-aGal assessed with artificial sub-
strate 4-nitrophenyl α-D-galactopyranoside was almost iden-
tical to that of agalsidase alfa (Fig. 1d). Km of moss-aGal and
agalsidase alfa were 6.5±0.2 and 6.8±0.3 mM; and Vmax of
these enzymes were 0.78±0.007 and 0.82±0.008 mmol/min/
mg, respectively.
Moss-aGal and high-mannose moss-aGal had almost the
same stability as agalsidase alfa or beta when diluted in human
plasma and heated at 37 °C (Fig. 1e).
In vitro uptake study
Fabry patients-derived fibroblasts were incubated with differ-
ent enzymes (10 μg/ml) overnight. Fibroblasts incubated with
agalsidase alfa or beta had markedly increased intracellular α-
gal A activities, and this uptake was nearly completely
inhibited by M6P and was partially inhibited by mannan
(Fig. 1f). Fibroblasts incubated with moss-aGal or high-
mann moss-aGal had a significantly lower increment of α-
gal A activities (Fig. 1f). This was consistent with little or no
expression of MR in these cells (Fig. 1h,i). Despite the low
uptake, lysosomal accumulation of Gb3 in Fabry patients’
fibroblasts was significantly decreased after treatment with
moss-aGal or high-mann moss-aGal for 4 days (Fig. 1g), in-
dicating that moss α-gal A enzymes are able to degrade the
accumulated substrates in the lysosomes.
Endothelial cells are a major disease-relevant cell type in
Fabry disease. We tested enzymatic uptake in Fabry patient-
derived microvascular endothelial cells (IMFE1). IMFE1 cells
originated from skin microvessels and were Bimmortalized^
by ectopic expression of telomerase reverse transcriptase.
These cells stably express many key markers and retain func-
tional characteristics of microvascular endothelial cells (Shen
et al 2007), and thus are a good in vitro model of human
endothelium. IMFE1 cells were MR-positive (Fig. 1h,i). It is
known that human dermal microvascular endothelia are MR-
positive in vivo. However, MR expression in primary cultured
microvascular endothelial cells decreased with subculture and
was absent at passage 5 (Groger et al 2000), suggesting MR
expression is prone to cellular senescence. The preserved ex-
pression of MR in IMFE1 cells and the low endogenous α-gal
A activity make this cell line a unique tool for uptake studies.
Expression of M6PR in IMFE1 was described previously
(Marchesan et al 2012). After overnight incubation, moss α-
gal A enzymes were efficiently taken up by IMFE1 cells
(Fig. 1j). This uptake was predominantly blocked (~60-
80 %) by mannan, suggesting it is mainly MR-mediated. Up-
take of agalsidase alfa or beta by IMFE1 was mostly inhibited
by M6P (~75-82 %).
In vitro uptake typically reaches a plateau phase after over-
night incubation. To compare uptake rates in a dynamic phase,
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IMFE1 cells were incubated with the enzymes for a shorter
time. Uptake of high-mann moss-aGal and agalsidase alfa was
approximately linear for up to 3 h, with significantly higher
uptake rate of high-mann moss-aGal than agalsidase alfa
(Fig. 1k). Uptake of moss-aGal was remarkably higher than
high-mann moss-aGal and agalsidase alfa after 1 h of incuba-
tion, and reached a plateau in 1–3 h (Fig. 1k). Immunoblot
confirmed these results at the protein level (Fig. 1l).
Binding of different enzymes to IMFE1 cells was assessed.
No α-gal A activity above background level was detected in
cells incubated with high-mann moss-aGal or agalsidase alfa.
Moss-aGal had significantly higher cellular binding than those
enzymes, and this binding was blocked by mannan but not by
M6P (Fig. 1m).
These results showed that in an assay system using cultured
endothelial cells, which is likely more relevant to in vivo ERT
than cultured fibroblasts, binding and uptake of moss α-gal A
enzymes are more efficient than for agalsidase alfa, and this
binding/uptake occurs through the MR. Since binding/uptake
of moss-aGal was more efficient than high-mann moss-aGal,
we selected the former for subsequent animal studies.
Plasma pharmacokinetics
After infusion, moss-aGal was more rapidly cleared from cir-
culation than agalsidase alfa when analyzed by enzyme
activities (Supplementary Fig. 2a). To verify that the shorter
plasma half-life of moss-aGal is due to more robust uptake by
tissues rather than faster enzyme inactivation, enzymes in
mouse plasma were also analyzed by immunoblot. α-Gal A
protein levels in moss-aGal-infused mice at 5 and 10 min after
infusion were significantly lower than in agalsidase alfa-
injected mice, and there was a strong correlation between
protein levels and enzyme activities in plasma (Supplementa-
ry Fig. 2b-d). Together with in vitro uptake study, these data
suggested that administered moss-aGal is more efficiently tak-
en up by vascular endothelial cells and other cell types com-
pared to agalsidase alfa.
Tissue and cellular distribution
Biodistribution of moss-aGal and agalsidase alfa at 2 h post-
injection was compared (Fig. 2a). Kidneys from moss-aGal-
injected mice had significantly higher enzyme activities than
those of agalsidase alfa-injected mice. The levels of moss-
aGal and agalsidase alfa in the heart and spleen were compa-
rable. The level of moss-aGal in the liver was significantly
lower than that of agalsidase alfa. Activities per whole organs
were calculated and ratios between different organs were com-
pared (Fig. 2b). Among total recovered activities, 94.9 % of
moss-aGal and 97.5 % of agalsidase alfa were delivered to the
livers (P<0.05). Kidneys of moss-aGal-injected mice had








Moss-aGal HexNAc2 Hex2 methyl-Hex Man3 + Methyl 2 24%
HexNAc2 Hex3 Man3 2 57%
(HexNAc2 Hex3) + HexNAc1 Man3 + 1x NAc 1 10%
(HexNAc2 Hex3) + HexNAc2 Man3 + 2x NAc 0 4%
(HexNAc2 Hex3) + (Hex)n Man5-8 3 4%
Unidentified 1%
High-mann (HexNAc2 Hex3) + Hex2 Man5 3 dominant
moss-aGal (HexNAc2 Hex3) + Hex1 Man4 2 few
(HexNAc2 Hex3) + Hex3 Man6 3 very few
(HexNAc2 Hex3) + Hex4 Man7 3 very few
Agalsidase- (HexNAc2 Hex3) + Hex3 3 2%
alfa (HexNAc2 Hex3) + Hex2 2 4%
(HexNAc2 Hex3) + HexNAc1 Hex2
(HexNAc2 Hex3 Fuc1) + HexNAc1 1 1%
Phosphorylated glycansa 0 24%
Diverse structuresa 0 63%
Unidentified                                                                                                     7%
m
N-glycans of moss-aGal and agalsidase alfa were analyzed quantitatively by HILIC-UPLC-MS
N-glycans of high-mann moss-aGal were analyzed as corresponding glycopeptides by ESI-Q-TOF mass spectrometry
Symbols in glycan structures: (white circle) mannose; (black square) GlcNAc; m, methyl group
aDetailed data are available upon request
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Fig. 1 In vitro characterization and uptake studies a Enzyme
preparations separated in SDS-PAGE and stained with Coomassie blue.
Lanes 1 and 2 are moss-aGal and agalsidase alfa respectively. Lanes 3 and
4 are moss-aGal and agalsidase alfa digested with PNGase F. Arrow, α-
gal A enzymes after digestion; arrowhead, PNGase F (36 KDa). Protein
standard and molecular weights are shown on left. b Moss-aGal and
agalsidase alfa (1 ng each) detected by western blot using a polyclonal
antibody specific to human α-gal A. Representative data from three in-
dependent experiments was shown. c Specific α-gal A activities of en-
zyme preparations determined using artificial substrate 4-MU-α-D-
galactopyranoside. d Plots of reaction velocities of moss-aGal and
agalsidase alfa assessed with artificial substrate 4-nitrophenyl α-D-
galactopyranoside (pNP-Gal). e Stability of the enzymes diluted in buff-
ered human plasma and heated at 37 °C (data are means of triplicates). f
Intracellular α-gal A activities of Fabry patient fibroblasts after overnight
incubation with different enzymes in the presence or absence of 5 mM
M6P or 2 mg/ml yeast mannan. g Gb3 immunofluorescence staining
shows massive lysosomal accumulation of Gb3 in untreated Fabry patient
fibroblasts (upper) and significantly decreased Gb3 in the cells that were
treated with moss-aGal (lower). h and i MR expression in Fabry patient
fibroblasts and microvascular endothelial cells IMFE1. IMFE1 cells were
MR-positive determined by both western blot (h) and immunofluores-
cence staining (i), while the fibroblasts were MR-negative. j Intracellular
α-gal A activities of IMFE1 cells after overnight incubation with different
enzymes in the presence or absence of M6P or mannan. kUptake rates of
different enzymes in IMFE1 cells. Cells were harvested at indicated time
points and intracellular activities were measured. ***P<0.001, moss-
aGal vs. high-mann moss-aGal or agalsidase alfa. lWestern blot analysis
of internalized α-gal A in IMFE1 cells after 3 h incubation with different
enzyme preparations. m Binding of different enzymes (10 μg/ml) to
IMFE1 cells. After 3 h incubation at 4 °C, cell surface-bound enzymes
were determined by enzyme assay. The dotted line indicates activity level
of mock-treated IMFE1 cells in this assay (i.e., background level).
*P<0.05, ***P<0.001. All the data in graphs are presented as mean±
SEM (n=3-4). High-mann: high-mann moss-aGal; Agal-alfa: agalsidase
alfa; Agal-beta: agalsidase beta
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1.96% of total activity, which is significantly higher (P<0.05)
than that in agalsidase alfa-injected mice (0.58 %). Immuno-
blot confirmed the higher uptake of moss-aGal in the kidney
compared to agalsidase alfa (Fig. 2c).
Cellular distribution of moss-aGal and agalsidase alfa
was assessed by immunohistochemistry (Fig. 2d). Spe-
cific signals displayed granular cytoplasmic pattern, pre-
sumably reflecting lysosomal localization of the enzyme.
Cellular localization of these two enzymes in the heart
and kidney was essentially identical. In hearts, both en-
zymes were detected in capillaries and perivascular
cells. In kidneys, specific staining was seen in cortical
tubular epithelial cells for either enzyme. These results
are consistent with distribution of agalsidase alfa de-
scribed previously (Murray et al 2007).
Tissue kinetics
Tissue kinetics of moss-aGal and agalsidase alfa were
investigated (Supplementary Fig. 3). At 2 and 24 h
post-injection, kidneys frommoss-aGal-injectedmice had sig-
nificantly higher enzyme activities compared to agalsidase
alfa-injected mice. However, activities were similar at 48
and 96 h. In the heart, there was no significant difference
between the two forms of enzymes at 2 and 24 h; however,
activities of moss-aGal were lower than agalsidase alfa at 48
and 96 h. In comparison to agalsidase alfa-injected mice,
moss-aGal-injected mice had similar levels of activities in
the spleen, and significantly lower activities in the liver
at all time points analyzed. The half-lives of moss-aGal
and agalsidase alfa in the kidney and heart ranged from
2 to 3 days. Moss-aGal had a ~25 % shorter half-life in
both organs. The half-life of moss-aGal in the liver was
significantly shorter compared to agalsidase alfa (24 vs.
57 h). The half-lives of both enzyme forms in the
spleen were similar (~30 h). The relatively shorter
half-life of moss-aGal in some organs is probably relat-
ed to the lower carbohydrate content that may lead to
increased susceptibility of the enzyme to proteolytic
degradation in the lysosomes.
Fig. 2 Tissue and cellular distribution of infused enzymes a-c Enzyme
preparations were injected into Fabry mice, and α-gal A activities in the
kidney, heart, spleen, and liver were measured 2 h post-injection. a Spe-
cific activities in organs. Data are presented as mean±SEM (n=5).
*P<0.05, **P<0.01. b Activities in whole organs were calculated and
data are presented as % of total activity recovered from four organs. c α-
gal A protein in kidney homogenates detected by western blot. Arrow,
specific α-gal A band in moss-aGal-injected mice. No detectable specific
band was seen in agalsidase alfa-injected mice. Arrowhead, approximate
position where agalsidase alfa band may migrate (based on findings
shown in Fig. 1b). d Cellular distribution of infused enzymes in the heart
and kidney was determined by immunohistochemistry (n=2). Heart: as-
terisks indicate the blood vessels with immunostaining positive cells
(most likely endothelial cells), and arrows indicate positive perivascular
cells (presumably macrophages). Kidney: arrows indicate immunostain-
ing positive tubular epithelial cells. Scale bar: 25 μm. Original magnifi-
cation: 400×. Agal-alfa: agalsidase alfa
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Tissue Gb3 clearance
Efficacies of moss-aGal and agalsidase alfa in degrading ac-
cumulated Gb3 were compared at 7 days after a single intra-
venous injection of either enzyme in 6-month-old Fabry mice.
Three different doses (0.3, 1, and 3 mg/kg) were tested. Both
forms of enzymes reduced Gb3 in kidney, heart, and liver in a
dose-dependent manner (Fig. 3a-c).Moss-aGal and agalsidase
alfa had comparable efficacy in clearing Gb3 in the kidney and
heart (Fig. 3a,b). In clearing liver Gb3, agalsidase alfa was
more effective than moss-aGal at doses of 0.3 and 1 mg/kg
(Fig. 3c). At a higher dose (3 mg/kg), these two enzymes led
to similar liver Gb3 levels.
Discussion
The present study provides new information on the relevance
of theMR-dependent endocytic pathway in infusing therapeu-
tic enzymes to treat systemic LSDs. Glycan structures and the
results of in vitro studies indicated that uptake of moss-aGal is
mediated by MR. The comparison of pharmacodynamic pro-
files of moss-aGal and agalsidase alfa in Fabry mice suggested
that mannose-terminated enzymes can be as effective asM6P-
harboring enzymes in the treatment of Fabry disease, and that
M6P residues may not always be a prerequisite for ERT as
generally believed. These findings may have important impli-
cations in developing new lysosomal enzymes in plant- and
other non-mammalian cell-based (e.g., insect cell and yeast)
expression systems, in which phosphorylation of mannosyl
residues is either lacking (in case of plant and insect cells) or
inadequate (in case of yeast). In yeast, mannose phosphoryla-
tion occurs, however, the phosphorylated sugars are capped
by terminal mannose residues (Ballou 1990) that block the
binding of M6PR to its ligands. Efforts have been applied to
add M6P tag to plant-made enzymes (He et al 2012), or in-
creaseM6P content or expose the coveredM6P in yeast-made
enzymes (Chiba et al 2002; Tsukimura et al 2012). Although
the role ofMR in the therapeutic outcome of ERTcan beα-gal
A-specific, our study proposed a possibility that mannose-
terminated enzymes produced from these non-mammalian
cell systems, without M6P manipulations, may be sufficiently
effective for some LSDs in which non-macrophage cells are
affected.
However, our results also suggest that MR-dependent en-
zyme uptake can be largely influenced by mannose chain
structures. In spite of increased terminal mannose residues,
binding/uptake of high-mann moss-aGal to endothelial cells
was significantly less efficient than moss-aGal. Similar find-
ings have been noted by a previous study (Van Patten et al
2007), in which the MR binding of glucocerebrosidase with
Man9GlcNAc2 was lower than that of Man3GlcNAc2. There-
fore, it is likely that the affinity of core-typeMan3GlcNAc2 for
theMR is higher than that of high-mannose type N-glycans on
lysosomal enzymes.
Fabry disease is one of the LSDs for which ERT has been
most extensively investigated. Enzymes produced frommam-
malian cells, yeast, insect cells, and plants have been tested in
in vitro and/or in vivo (Chen et al 2000a, b; Ioannou et al
2001; Chiba et al 2002; Tsukimura et al 2012; Kizhner et al
2015). The test ofα-gal A produced in Chinese hamster ovary
cells provided a prototype for the assessment of recombinant
α-gal A in Fabry mice (Ioannou et al 2001). Recently,α-gal A
produced from tobacco cells (PRX-102) was reported
(Kizhner et al 2015). Like moss-aGal, PRX-102 is non-phos-
phorylated. However, this protein is chemically modified,
resulting in a cross-linked dimer of PEGylated subunits. These
modifications are associated with significant changes in pro-
tein characteristics, including different enzyme kinetics and
dramatically prolonged circulation half-life (~10 h) compared
with agalsidase alfa or beta. The uptake mechanism of PRX-
102 remains to be elucidated. However, remarkably slow plas-
ma clearance suggests that the uptake is not via M6PR- or
MR-mediated endocytosis.
The present study demonstrated the therapeutic potential of
moss-aGal as a new form of enzyme drug to treat Fabry dis-
ease. Moss-aGal protein is identical to its human counterpart
with respect to amino acid sequence and dimeric structure.
Moss-aGal has unique N-glycans that are predominantly
core-type and are highly homogeneous. High degree of tri-
mannosyl N-glycans was obtained on moss-aGal without
using C-terminal vacuolar targeting signal. The latter is an
often-used strategy in plant expression systems to achieve
exposed mannosyl residues by sorting recombinant proteins
to vacuolar compartments instead of Golgi complex. Down-
sides of this strategy are that the additional amino acids will
remain in the final protein product and purification of the
protein requires extraction from a whole cell lysate.
Due to depletion of plant-specific glycosyltransferases in
the host strain, moss-aGal does not have α-(1,3)-fucose and
β-(1,2)-xylose residues, hence avoiding potential immunolog-
ical reaction against these plant-specific sugar chains. In gen-
eral, development of antibodies to the infused agalsidase alfa
or beta is common in enzyme therapy for Fabry patients, es-
pecially in males, which may affect the efficacy and safety of
the treatment (Deegan 2012). Sugar chains exert important
roles in modulating the antigenicity of therapeutic proteins
(Costa et al 2014), thus the distinct glycosylation profile of
moss-aGal from that of agalsidase alfa or beta will likely lead
to a different immunological response in the human body.
This should be investigated in future studies.
The uptake of moss-aGal by IMFE1 cells was more effi-
cient than that of agalsidase alfa. Given that endothelial cells
may play roles in the pathophysiology of vasculopathy and
other manifestations in Fabry disease, the better delivery to
vascular endothelial cells could be advantageous. Uptake of
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agalsidase alfa and beta by endothelial cells involved bothMR
and M6PR, with the latter as preferential pathway. The less
efficient endothelial uptake of agalsidase alfa compared to
moss-aGal is probably due to lower abundance of M6PR in
these cells relative to MR. The low expression of plasma
membrane M6PR in human endothelial cells demonstrated
byMarchesan (Marchesan et al 2012) supports this possibility.
However, discrepancies exist between the same study by
Marchesan et al and ours with respect to uptake mechanism
of agalsidase alfa/beta in endothelial cells. Their study found
noM6PR-mediated binding/uptake and little lysosomal deliv-
ery of α-gal A in human endothelial cells. By contrast, data
from our present and previous studies suggested that M6PR
pathway is the dominant contributor for uptake of agalsidase
alfa/beta in IMFE1 cells, and that the enzyme is delivered into
lysosomes, as evidenced by the robust clearance of lysosomal
Gb3 in enzyme-treated cells (Shen et al 2007). These discrep-
ancies may be due to methodological differences. For exam-
ple, Marchesan and coworkers used fluorescence detection of
labeled α-gal A for uptake and lysosomal delivery of the en-
zyme, while we used enzyme assay and Gb3 immuno-
cytochemistry.
Nevertheless, it should be noted that vascular endothelium
is readily accessed by intravenously administered α-gal A
(Eng et al 2001a, b; Schiffmann et al 2001). Cardiomyocytes,
podocytes, and peripheral neurons represent the major hard-
to-reach cell types in current ERT for Fabry disease. It remains
unclear whether moss-aGal offers improved delivery to these
cell types compared with existing enzymes, because we could
not detect any infused enzyme in cardiomyocytes and
podocytes by immunohistochemistry, possibly due to lower
sensitivity of the method.
Relative to agalsidase alfa, targeting of moss-aGal to the
kidney was significantly enhanced and delivery to the liver
was significantly reduced. The mechanism for this differential
tissue distribution is unclear. One possibility is that the lower
uptake of moss-aGal by the liver might contribute to relatively
increased uptake by the kidney. However, this cannot explain
the absence of relative increased uptake of moss-aGal by the
heart and spleen compared to agalsidase alfa. Thus, it is likely
that there is a more specific mechanism that targets moss-aGal
preferentially to the kidney. Because the infused enzyme was
only detected in cortical tubules by immunostaining, a large
part of α-gal A activity in the kidney must have been from the
tubules, suggesting that the higher renal distribution of moss-
aGal may be due to the higher uptake of tubular cells. How-
ever, renal tubules were not reported to express MR (Linehan
et al 1999). A potential interpretation is that tubular cells ex-
press MR, but at a relatively low level that could not be de-
tected, or that they express other receptor(s) that mediate en-
docytosis of mannose-terminated glycoproteins. The presence
of such unidentified receptor(s) that have MR-like binding
activity has been reported in murine spleens and lymph nodes
(Linehan et al 1999). Another possibility is endocytosis
through other receptors that recognize non-carbohydrate li-
gands. It is known that megalin and/or sortilin work as α-gal
A receptors in tubular cells, podocytes and glomerular endo-
thelial cells (Christensen et al 2007; Prabakaran et al 2011,
2012). Further studies are needed to test whether moss-aGal
has higher affinity for these receptors compared to mammali-
an cell-produced enzymes, and thus leads to better renal
distribution.
Our study also provided new insight into endocytic path-
ways for the phosphorylated form of α-gal A. As mentioned,
both M6PR and MR mediate delivery of agalsidase alfa
in vitro, thus it is difficult to determine which receptor path-
way is more responsible for the biodistribution of this enzyme
in target organs. Despite markedly different sugar chains, cel-
lular localization of agalsidase alfa and moss-aGal in the heart
and kidney was surprisingly similar. Storage clearance effica-
cy in these organs was similar as well. In other words, com-
pared to a completely non-phosphorylated enzyme, M6P res-
idues in agalsidase alfa did not lead to a wider distribution and
more complete Gb3 clearance as one might expect. These
Fig. 3 Efficacy of moss-aGal in clearing accumulated Gb3 in tissues.
Gb3 contents in kidney (a), heart (b), and liver (c) were analyzed 7 days
after a single infusion of either moss-aGal or agalsidase alfa at various
doses. Data are presented as mean±SEM (n=4-5). *P<0.05,
***P<0.001. Statistical significance shown on top of each agalsidase
alfa-injected group indicates difference between agalsidase alfa and the
same dose of moss-aGal. Agal-alfa: agalsidase alfa
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findings suggested that the MR pathway might play a more
important role than M6PR in targeting agalsidase alfa to the
heart and kidney. These findings are different from those of
previous studies that suggested the importance of M6P in
delivery of β-glucuronidase and acid α-glucosidase (Sands
et al 2001; Zhu et al 2009). The discrepancy between α-gal
A and these enzymes suggests that the impact of M6P in ERT
can be enzyme-specific.
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